We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Halozyme's (HALO) Q1 Earnings Beat, Revenues Lag Estimates
Read MoreHide Full Article
Halozyme Therapeutics, Inc. (HALO - Free Report) reported first-quarter 2024 adjusted earnings of 79 cents per share, which surpassed the Zacks Consensus Estimate of 69 cents. The company had recorded earnings of 47 cents per share in the year-ago period.
Total revenues increased 21% year over year to $195.9 million in the first quarter. The top line was driven by higher royalty payments from J&J (JNJ - Free Report) for subcutaneous Darzalex (daratumumab) and Roche (RHHBY - Free Report) for Phesgo, as well as increased milestone payments from collaboration partners.
Revenues, however, missed the Zacks Consensus Estimate of $202 million.
Several companies use HALO’s Enhanze technology to develop a subcutaneous formulation of their currently marketed drugs. Halozyme now has six marketed partnered drugs based on this technology, including the subcutaneous formulation of J&J’s Darzalex and Roche’s Phesgo.
Shares of Halozyme have rallied 11.5% year to date against the industry’s decline of 6.2%.
Image Source: Zacks Investment Research
Quarter in Detail
Halozyme’s top line comprises product sales, royalties and revenues under collaborative agreements.
Royalty revenues totaled $120.6 million in the first quarter, up 21% from the year-ago quarter’s level. This was mainly due to robust demand for Darzalex and Phesgo. Royalty revenues accounted for nearly 61.5% of the company’s total revenues in the reported quarter. Royalty revenues beat our model estimate of $114.3 million.
Product sales came in at $58.6 million, down 3.6% from the year-ago quarter figure. HALO supplies API to ENHANZE partners like JNJ and RHHBY, contributing to revenues as well as higher sales of the proprietary product Xyosted, which was acquired from Antares Pharma in 2022. Product sales missed our model estimate of $71.1 million.
Revenues under collaborative agreements were $16.7 million in the first quarter, up from $1.7 million reported in the year-ago quarter.
Adjusted EBITDA was $115.7 million in the first quarter, reflecting a 55.7% increase from the prior-year quarter.
Halozyme had cash, cash equivalents and marketable securities of $463.5 million as of Mar 31, 2024, compared with $336 million as of Dec 31, 2023.
2024 Guidance
Halozyme reiterated its guidance for 2024 provided earlier this year.
The company still expects total revenues in the range of $915-$985 million in 2024, implying year-over-year growth of 10% to 19% on higher royalty revenue, collaboration revenues and growth in product sales from Xyosted.
Revenues from royalties are anticipated in the range of $500-$525 million.
Adjusted EBITDA is expected in the range of $535-$585 million, implying year-over-year growth of 26% to 37%.
The company expects adjusted earnings in the range of $3.55-$3.90 per share, indicating an improvement of 28% to 41% year over year. Halozyme’s earnings per share guidance does not consider the impact of potential future share repurchases.
In February 2024, Halozyme announced a third share repurchase program to buy back up to $750 million of the company’s common stock.
Halozyme Therapeutics, Inc. Price, Consensus and EPS Surprise
Image: Bigstock
Halozyme's (HALO) Q1 Earnings Beat, Revenues Lag Estimates
Halozyme Therapeutics, Inc. (HALO - Free Report) reported first-quarter 2024 adjusted earnings of 79 cents per share, which surpassed the Zacks Consensus Estimate of 69 cents. The company had recorded earnings of 47 cents per share in the year-ago period.
Total revenues increased 21% year over year to $195.9 million in the first quarter. The top line was driven by higher royalty payments from J&J (JNJ - Free Report) for subcutaneous Darzalex (daratumumab) and Roche (RHHBY - Free Report) for Phesgo, as well as increased milestone payments from collaboration partners.
Revenues, however, missed the Zacks Consensus Estimate of $202 million.
Several companies use HALO’s Enhanze technology to develop a subcutaneous formulation of their currently marketed drugs. Halozyme now has six marketed partnered drugs based on this technology, including the subcutaneous formulation of J&J’s Darzalex and Roche’s Phesgo.
Shares of Halozyme have rallied 11.5% year to date against the industry’s decline of 6.2%.
Image Source: Zacks Investment Research
Quarter in Detail
Halozyme’s top line comprises product sales, royalties and revenues under collaborative agreements.
Royalty revenues totaled $120.6 million in the first quarter, up 21% from the year-ago quarter’s level. This was mainly due to robust demand for Darzalex and Phesgo. Royalty revenues accounted for nearly 61.5% of the company’s total revenues in the reported quarter. Royalty revenues beat our model estimate of $114.3 million.
Product sales came in at $58.6 million, down 3.6% from the year-ago quarter figure. HALO supplies API to ENHANZE partners like JNJ and RHHBY, contributing to revenues as well as higher sales of the proprietary product Xyosted, which was acquired from Antares Pharma in 2022. Product sales missed our model estimate of $71.1 million.
Revenues under collaborative agreements were $16.7 million in the first quarter, up from $1.7 million reported in the year-ago quarter.
Adjusted EBITDA was $115.7 million in the first quarter, reflecting a 55.7% increase from the prior-year quarter.
Halozyme had cash, cash equivalents and marketable securities of $463.5 million as of Mar 31, 2024, compared with $336 million as of Dec 31, 2023.
2024 Guidance
Halozyme reiterated its guidance for 2024 provided earlier this year.
The company still expects total revenues in the range of $915-$985 million in 2024, implying year-over-year growth of 10% to 19% on higher royalty revenue, collaboration revenues and growth in product sales from Xyosted.
Revenues from royalties are anticipated in the range of $500-$525 million.
Adjusted EBITDA is expected in the range of $535-$585 million, implying year-over-year growth of 26% to 37%.
The company expects adjusted earnings in the range of $3.55-$3.90 per share, indicating an improvement of 28% to 41% year over year. Halozyme’s earnings per share guidance does not consider the impact of potential future share repurchases.
In February 2024, Halozyme announced a third share repurchase program to buy back up to $750 million of the company’s common stock.
Halozyme Therapeutics, Inc. Price, Consensus and EPS Surprise
Halozyme Therapeutics, Inc. price-consensus-eps-surprise-chart | Halozyme Therapeutics, Inc. Quote
Zacks Rank & Stock to Consider
Halozyme currently has a Zacks Rank #3 (Hold).
A top-ranked stock in the healthcare sector is Ligand Pharmaceuticals Incorporated , sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Ligand’s 2024 earnings per share have improved from $4.42 to $4.56. Year to date, shares of LGND have risen 2.5%.
Earnings of LGND beat estimates in each of the trailing four quarters, the average surprise being 84.81%.